Diagnosis and management of spinal muscular atrophy : Part 1: Recommendations for diagnosis, rehabilitation, orthopedic and nutritional care by E. Mercuri et al.
Diagnosis and management of spinal muscular atrophy: Part 1:
Recommendations for diagnosis, rehabilitation,
orthopedic and nutritional care
Eugenio Mercuri a,b,1,*, Richard S. Finkel c,1, Francesco Muntoni d, Brunhilde Wirth e,
Jacqueline Montes f, Marion Main d, Elena S. Mazzone a,b, Michael Vitale g, Brian Snyder h,
Susana Quijano-Roy i,j, Enrico Bertini k, Rebecca Hurst Davis l, Oscar H. Meyer m,
Anita K. Simonds n, Mary K. Schroth o, Robert J. Graham p, Janbernd Kirschner q,
Susan T. Iannaccone r, Thomas O. Crawford s, Simon Woods t, Ying Qian u, Thomas Sejersen v for
the SMA Care Group
a Paediatric Neurology Unit, Catholic University, Rome, Italy
b Centro Clinico Nemo, Policlinico Gemelli, Rome, Italy
c Nemours Children’s Hospital, University of Central Florida College of Medicine, Orlando, FL, USA
d Dubowitz Neuromuscular Centre, UCL Great Ormond Street Institute of Child Health & Great Ormond Street Hospital, London, UK
e Institute of Human Genetics, Center for Molecular Medicine, Center for Rare Diseases and Institute for Genetics, University of Cologne, Germany
f Departments of Rehabilitation and Regenerative Medicine and Neurology, Columbia University Medical Center, New York, NY, USA
g Department of Orthopaedic Surgery, Columbia University Medical Center, New York, NY, USA
h Department of Orthopaedic Surgery, Children’s Hospital, Harvard Medical School, Boston, USA
i Assistance Publique des Hôpitaux de Paris (AP-HP), Unit of Neuromuscular Disorders, Department of Pediatric Intensive Care, Neurology and Rehabilitation,
Hôpital Raymond Poincaré, Garches, France
j Hôpitaux Universitaires Paris-Ile-de-France Ouest, INSERM U 1179, University of Versailles Saint-Quentin-en-Yvelines (UVSQ), Paris, France
k Unit of Neuromuscular & Neurodegenerative Disorders, Dept of Neurosciences & Neurorehabilitation, Bambino Gesù Children’s Research Hospital, Rome, Italy
l Intermountain Healthcare, University of Utah, Salt Lake City, UT, USA
m Division of Pulmonology, The Children’s Hospital of Philadelphia, Philadelphia, PA, USA
n NIHR Respiratory Biomedical Research Unit, Royal Brompton & Harefield NHS Foundation Trust, London, UK
o Division of Pediatric Pulmonary, Department of Pediatrics, University of Wisconsin School of Medicine and Public Health, American Family Children’s
Hospital, Madison, WI, USA
p Division of Critical Care, Dept of Anesthesiology, Perioperative & Pain Medicine, Boston Children’s Hospital, Harvard Medical School, Boston, MA, USA
q Department of Neuropediatrics and Muscle Disorders, Medical Center, Faculty of Medicine, University of Freiburg, Freiburg, Germany
r Departments of Pediatrics and Neurology and Neurotherapeutics, Division of Pediatric Neurology, University of Texas Southwestern Medical Center and
Children’s Medical Center Dallas, USA
s Department of Neurology, Johns Hopkins University, Baltimore, MD, USA
t Policy Ethics and Life Sciences Research Centre, Newcastle University, Newcastle, UK
u SMA Foundation, New York, NY, USA
v Department of Women’s and Children’s Health, Paediatric Neurology, Karolinska Institute, Stockholm, Sweden
Received 3 September 2017; received in revised form 6 November 2017; accepted 13 November 2017
Abstract
Spinal muscular atrophy (SMA) is a severe neuromuscular disorder due to a defect in the survival motor neuron 1 (SMN1) gene. Its incidence
is approximately 1 in 11,000 live births. In 2007, an International Conference on the Standard of Care for SMA published a consensus statement
on SMA standard of care that has been widely used throughout the world. Here we report a two-part update of the topics covered in the previous
recommendations. In part 1 we present the methods used to achieve these recommendations, and an update on diagnosis, rehabilitation, orthopedic
and spinal management; and nutritional, swallowing and gastrointestinal management. Pulmonary management, acute care, other organ
involvement, ethical issues, medications, and the impact of new treatments for SMA are discussed in part 2.
© 2018 The Authors. Published by Elsevier B.V. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).
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1. Introduction
Spinal muscular atrophies (SMA) include a group of
neuromuscular disorders characterized by degeneration of
alpha motor neurons in the spinal cord with progressive muscle
atrophy, weakness and paralysis [1]. The most common form of
SMA is due to a defect in the survival motor neuron 1 (SMN1)
gene localized to 5q11.2-q13.3 [2]. It includes a wide range of
phenotypes that are classified into clinical groups on the
basis of age of onset and maximum motor function achieved:
very weak infants unable to sit unsupported (type 1), non-
ambulant patients able to sit independently (type 2), up to
ambulant patients with childhood (type 3) and adult onset SMA
(type 4).
In 2004 an International Conference established a
committee of experts in SMA to create a consensus statement
on SMA standard of care [3]. Different working groups were
established, addressing different aspects of diagnosis and
management, focusing on rehabilitation and orthopedic,
pulmonary, nutritional and palliative care. Each group had two
leaders, facilitating the work of other experts who were invited
to participate. The Delphi technique [4] was used to explore
consensus expert opinion and to identify topics where no
consensus could be reached for which further study was
needed.
A report of the SMA SOC consensus statement was
published in 2007 [3]. The guidelines have been widely
adopted by clinicians all over the world and were translated
and promoted by patient advocacy groups and international
neuromuscular networks such as TREAT-NMD. More
recently, with the advent of clinical trials in SMA [5–8],
the guidelines have also been used in protocols as a benchmark
for care for recruitment and during participation in a clinical
trial.
Over the last decade there has been increasing evidence of
improvements in the natural history of all the SMA types
[9–11]. Even in type 1, the most severe form of SMA, there has
been an increase of survival as a result of a more proactive
approach, following the introduction of non-invasive
ventilation and enteral feedings, suggested in the original SOC
recommendations [12,13]. These improvements are likely to be
the result of the recommendations provided in the consensus
statement and of new advances in care that are not always
reflected in the existing literature.
In this paper we report an update of the consensus statement,
following the need to include more recently published data and
more generally advances in the topics addressed in the original
version. New aspects, such as those related to acute and
emergency care, medications or the involvement of other
organs have also been added.
The need for an update has also been driven by the
advent of clinical trials [14]. The approval of the first drug
for SMA in December 2016 and promising early results
from other clinical trials have changed the perspective of
physicians and families who are now more willing to be
proactive in the management of this disorder, especially in
type 1.
2. Method
Nine topics were included in this update:1. Diagnosis
and genetics; 2. Physical therapy and rehabilitation; 3.
Orthopaedic care, growth and bone health care; 4. Nutrition; 5.
Pulmonary care; 6. Acute care in the hospital setting; 7. Other
organ system involvement; 8. Medication; 9. Ethics and
palliative care.
For each topic, two leaders, in most cases one from Europe
and one from the United States, were identified to head a
working group inviting other clinicians with expertise in the
topic and, when appropriate, at least one SMA patient or parent/
caregiver. The choice of the participants in each subgroup was
based on strict criteria, inviting the experts from all continents
who had published on the specific topic, or had a large
experience in the field and were part of national or international
working groups.
A literature search identified all the relevant articles that
were classified according to their consistency with the previous
recommendations [3], or whether they included novel or
contrasting findings.
Each working group (WG) had 2 preliminary conference
calls, and at least 2 web-based Delphi rounds of inquiry. The
first round of Delphi used open-ended questions to generate
specific topics. The second round focused on the topics ranked
the highest on the first round.
The review of the literature and the results of the first two
rounds were analyzed and discussed in an in-person workshop
where the leaders of all the working groups convened. The
American Academy of Pediatrics guidelines for classifying
recommendations for clinical practice [15] were used to analyze
the results.
Within each working group, each topic was summarized as
to where a) Consensus was reached with uniform opinion; b)
Consensus was reached with a majority opinion, and with
minority opinions mentioned; c) No consensus is reached and
more work has to be performed.
Following the workshop, more rounds of Delphi were
performed to further define some aspects requiring further
definition, highlighted during the workshop. Details of the
methodology used have been recently published in the
workshop report [16].
The results were subdivided using the functional
classification from the original consensus statement document.
Considering that type 3 patients who lost ambulation share
many aspects with type 2 patients, the two groups are
collectively indicated as “sitters”, while the type 3 patients who
are still ambulant are indicated as “walkers”. Type 1 patients are
indicated as non-sitters.
2.1. SMA diagnosis
The diagnostic process for SMA has not changed since the
original consensus statement paper [3] but more accurate
information on the genetic background has become available.
Unless there are previous familial cases, the diagnostic
process is generally prompted by the clinical signs. Clinically,
these infants present with hypotonia, progressive symmetric
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and proximal weakness affecting the legs more than the arms,
sparing of the facial muscles but often with bulbar muscle
weakness. There is also weakness of the intercostal muscles
with relative sparing of the diaphragm, which results in the
typical “bell-shaped” chest and paradoxical breathing pattern.
Childhood onset is similarly characterized by hypotonia and
proximal weakness, but with less prominent bulbar and
respiratory findings.
In approximately 96% of patients, SMA is caused by
homozygous absence of exons 7 and 8 of the SMN1 gene, or, in
some cases, only of exon 7 [2,17–20]. The majority of patients
inherit the SMN1 deletion from their parents; in 2% de-novo
deletions in one of the 2 alleles have been described [21]. In
3–4%, other mutations in SMN1 can be found, typically with an
SMN1 deletion on the other allele [22].
Population studies have indicated variations in the carrier
frequency of SMN1 deletions, with the Asians having the
highest carrier frequency (2.4%) [23]. The SMN locus is part of
a genomic inverted duplication region on human chromosome
5, which contains a paralogue gene, SMN2. SMN2 is intact in all
SMA patients. The SMN2 copy numbers however can vary
between 0 and 4 per chromosome 5 in the general population.
SMA patients always carry at least 1 SMN2 copy.
The diagnosis of SMA is based on molecular genetic testing.
Genetic testing of SMN1/SMN2 is highly reliable and it is first
line investigation when the condition is suspected in a typical
case (Fig. 1). In a typical presentation there is no need for a
muscle biopsy.
EMG is also usually not needed in type 1 and 2 children; this
investigation can help in more chronic forms in which the
phenotype might be less striking. CK serum levels are usually
normal or only mildly elevated in SMA; however few exception
with markedly (10×) elevated levels are on record hence this
test does not necessarily exclude the diagnosis [24].
The gold standard of SMA genetic testing is a quantitative
analysis of both SMN1 and SMN2 using multiplex ligation-
dependent probe amplification (MLPA), quantitative polymerase
chain reaction (qPCR) or next generation sequencing (NGS)
[23,25–27]. Homozygous SMN1 deletions can be identified
also by PCR followed by restriction digest. This method is
faster and is less expensive, and often readily available in any
lab but does not allow quantification of SMN1 or SMN2 copy
number. However, knowledge on SMN1 copies is relevant for
identification of heterozygous deletions whereas SMN2 copies
are important for prognosis and therapeutic approaches.
The absence of both full SMN1 copies will provide diagnosis
of SMA. If only 1 full copy is present and clinical phenotype is
compatible with SMA, the remaining SMN1 gene should be
sequenced looking for other subtle mutations. If both full SMN1
copies are present, a diagnosis of SMA is highly unlikely but
the SMN1 gene should be sequenced if there is a striking typical
phenotype or consanguinity. If sequencing indicates an intact
SMN1 gene in the presence of a phenotype suggestive of SMA
including also neurogenic EMG, other motor neuron diseases
should be considered.
There was consensus that even if the number of SMN2
copies is not essential to reach the diagnosis of SMA, this
should be routinely assessed as it is an important factor
influencing the severity of the SMA phenotype [26,28–30]
(Supplementary Table S1).
The majority of type 1 SMA patients carry two SMN2
copies, type 2 SMA and type 3a SMA patients (onset before the
age of 3 years) three SMN2 copies, type 3b SMA patients (age
of onset after 3 years) four SMN2 copies, and type 4 four to six
copies [26,30]. Although there is a strong correlation between
SMN2 copies and severity of the disease, there are exceptions
and in individual cases the number of SMN2 copies may not
predict the severity of the phenotype. This limitation should be
Fig. 1. Diagnostic algorithm for spinal muscular atrophy (SMA: spinal muscular atrophy; SMN1: survival motor neuronon 1; SMN2: survival motor neuron 2;
NMD: neuromuscular disorders; EMG: electromyography; NCV: nerve conduction velocity; CK: creatine kinase levels;WES: whole exom sequencing;WGS: whole
genome sequencing).
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mentioned when reporting the number of copies or counseling
patients or their families.
Another reason for determining the number of SMN2 copies
is that this is currently used as a criterion for enrolment of
patients into clinical trials [7,8].
Presence of SMN1 but homozygous absence of SMN2, a
genotype found in about 3–5% of control individuals, has no
apparent phenotypic consequences [2,20]. The presence of at
least one fully functional SMN1 gene, as typically found in
SMA carriers, is indeed sufficient to protect from SMA.
Genetic counseling is obviously important at the time of
diagnosis, as is psychological support to the families, especially
when a diagnosis of type 1 SMA is communicated.
2.2. Management: a multidisciplinary approach
A multidisciplinary approach is the key element in the
management of SMA patients [1,3]. SMA is a complex disorder
involving different aspects of care and professionals, and each
of the aspects should not be dealt in isolation but as part of a
multidisciplinary approach (Fig. 2). In the past families had to
coordinate all the assessments and visits but it is now
recommended that this should be coordinated by one of the
physicians, generally the neurologist or pediatric neurologist,
who is aware of the disease course and potential issues. This
will allow to monitor the various aspects that are known to be
part of the disease progression and, when possible, to provide
anticipatory care.
2.3. Neuromuscular and musculoskeletal evaluation
Clinical assessment in SMA includes performing a physical
examination, with a focus on the musculoskeletal system and
related functional impairments. The choice of the assessments
used will reflect the aspects that are more relevant for each level
of severity (Supplementary Table S2).
These should include different means of assessments of
strength and range of joint motion, relevant motor functional
scales [31–35] and timed tests to monitor those aspects of
function that reflect activities of daily living (Table 1).
These assessments should be performed routinely by trained
examiners every 6 months, unless there are special
circumstances requiring different follow up.
Regular monitoring of these aspects will allow to monitor
possible changes over time, to identify aspects requiring
intervention and response to intervention. The use of these
assessments also allows to compare individual results to the
trajectories of progression reported in recent studies [36,37].
2.4. Rehabilitation
Since the original consensus statement paper there has been
increasing evidence that a proactive approach, including regular
sessions of physical therapy (PT) may influence trajectories of
progression. In a recent study on sitters and walkers, functional
changes over 12 months were minimal in the whole cohort and
the few outliers showing a more substantial loss of functional
activities were often those with increase in their joint
contractures, sudden scoliosis deterioration or excessive weight
gain [36]. Other papers have reported the benefits of braces,
orthoses and exercise [38–45] (Supplementary Table S3).
2.4.1. Non-sitters
The primary rehabilitation goals for non-sitters include:
optimization of function, minimization of impairment, and
optimizing tolerance to various positions (Table 1).
2.4.1.1. Stretching. This includes the use of orthoses and
splints, active-assistive and passive techniques, supported
supine/standing/standing frames and serial casting. Thoracic
bracing is recommended for postural stabilization and to
promote function. Cervical bracing is often used for head
support particularly, as head control is often absent or not fully
developed, to minimize risk of asphyxiation while upright.
Upper and lower limb orthoses are used to promote function
and range of motion.
2.4.1.2. Positioning. Seating systems and postural supports
should include supine positioning with rolls, beanbags, molded
pillows or wedges. Custom and molded wheelchair seating
systems as well as custom sleeping systems are recommended.
To promote mobility and transfers the use of strollers and
power wheelchairs with recline/tilt options and adapted seating
systems are recommended.
2.4.1.3. Mobility and exercise. To promote function, assistive
technology and adaptive equipment are recommended. The use
of eye tracking devices is also recommended to improve
communication. Some non-sitters can participate safely in
aquatic therapy with proper head and neck support and constant
supervision.
2.4.1.4. Chest physiotherapy. Chest physiotherapy is an
important part of the assessment and management. It is
Fig. 2. Multidisciplinary approach.
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Table 1
Rehabilitation assessment and intervention.
Assessment Intervention Care considerations
Non-sitters Postural control
Scoliosis
Hip dislocation
Sitting tolerance
Chest deformities
Positioning and Bracing
Daily use of seating systems, postural and
positioning supports, thoracic bracing and cervical
bracing for head support.
Static thoracic bracing should have incorporated
modifications for respiratory support including
abdominal cutouts.
To be effective, orthoses should be applied for more than 60
minutes to overnight.
Session duration for effective stretching and range of motion
depends on specific patient needs, joints, and rehabilitation
aims.
Contractures (ROM,
goniometry)
Stretching
Daily use of orthoses for upper lower limb orthoses
for stretching and to promote function and range of
motion.
Static orthoses Knee immobilizers and hand splints
are recommended for positioning and stretching.
AFOs and KAFOs can be used for stretching and
positioning. TLSOs are used for positioning.
Supported standing
The minimal frequency for stretching and range of motion is
3–5 times per week
The minimal frequency for bracing to be effective is 5 times
per week.
Muscle weakness
(Antigravity movements)
Functional scales (CHOP
INTEND)
Motor development (HINE)
Promote function and mobility
Use of seating and mobility systems
Mobile arm supports to assist upper extremity
function.
Recommend toys with switches, light weight rattles,
Bath equipment, adapted beds, upper extremity assistive
devices, as well as hoists (lifts),
Environmental controls, and eye tracking devices for
computers and communication,
Strollers with recline and the ability to lay flat, power
wheelchairs should have recline/tilt, adapted seating systems
Sitters Postural control
Foot and chest deformities
Scoliosis and pelvic obliquity
Hip dislocation
Positioning and Bracing
Thoracic bracing is recommended for posture and
to promote function.
Cervical bracing is often used for head support for
safety and transportation.
Orthoses should be worn for more than 60 minutes to
overnight.
The minimal frequency for bracing: 5 times/week.
Contractures (ROM,
goniometry)
Stretching
Orthoses are used for the upper and lower limbs to
promote function and ROM
Regular stretching for segments known to be at risk
for contractures: hip, knee and ankle, wrist and
hand
Knee immobilizers, KAFOs, and AFOs are
recommended for positioning and standing. RGOs
and KAFOs can be used for supported ambulation.
TLSOs and hand splints are used for positioning.
Minimal frequency for stretching and ROM: 5–7 times/week
When stretching or performing joint mobilization ensure joint
segments are aligned throughout the treatment.
Supported standing should be up to 60 minutes and minimal
frequency is 3–5 times/week, optimal 5–7 times/week.
Functional scales (HFMSE,
RULM, MFM)
Muscle weakness (Strength
tests)
Promote function and mobility
Use of seating and mobility systems.
Use of gait training devices and mobility devices to
promote supported ambulation
Mobile arm supports to assist upper extremity
function.
Exercise can have an effect on function, strength, ROM,
endurance, ADLs, participation, and balance
Recommend swimming, hippotherapy, and wheelchair sports.
All sitters should have electric/power wheelchairs with custom
postural support and seating systems
The option to tilt and/or recline and a seat elevator is
sometimes necessary in weaker patients.
Lightweight manual wheelchairs or power assist wheels are
ideal to promote self-propulsion in stronger patients.
Ambulant Mobility
Timed tests
Measure of endurance
(6MWT)
Falls
Functional scales (HFMSE,
RULM)
Muscle weakness (Strength
tests)
Promote function and mobility Recommend aerobic and general conditioning exercise for
SMA walkers. Options include: Swimming, walking, cycling,
yoga, hippotherapy, rowing, elliptical/cross-trainers.
Exercise program should be designed and monitored by a
physical or occupational therapist, familiar with SMA.
Optimal duration for aerobic exercise: at least 30 minutes
Contractures (ROM,
goniometry)
Stretching Minimal frequency: 2–3 times/week, optimal: 3–5
Maintain flexibility through active assisted stretching and
include the use of orthoses according to specific needs.
Postural control
Scoliosis
Hip dislocation
Positioning and Bracing Recommend some form of balance exercise.
Lower limb orthoses are used for posture and function at the
ankle and knee, Thoracic bracing may be used to promote
posture in sitting
ROM, range ofmotion; CHOP INTEND,ChildrenHospital of Philadelphia InfantTest of Neuromuscular Disorders; HINE,Hammersmith Infant Neurological Examination;
AFOs, ankle foot orthosis; KAFOs, knee ankle foot orthosis; TLSOs, thoraco lumbo sacral orthosis; HFMSE, Hammersmith Function Motor Scale Expanded; RULM,
Revised Upper Limb Module; MFM, Motor Function measure; 6MWT, 6 minute walk test; ADL, activities of daily living; SMA, spinal muscular atrophy.
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particularly important to implement during illness or
perioperative periods and as prophylaxis pulmonary
management to promote airway clearance and improve
ventilation. Manual techniques include percussion, vibration
and positioning to promote postural drainage.
2.4.2. Sitters
The main objectives for rehabilitation in sitters are to prevent
contractures and scoliosis, and maintain, restore or promote
function and mobility.
2.4.2.1. Stretching. Modalities for stretching include
techniques that can be achieved manually and through the use
of orthoses, splints, active-assistive stretching, supported
standing/standing frames and positioning techniques such as
serial casting. Stretching modalities should be performed
and/or supervised by physical or occupational therapists.
Parents and caregivers should also be instructed in daily
stretching activities.
Session duration for effective stretching depends on specific
patient needs, joints, and rehabilitation aims.
2.4.2.2. Positioning. Thoraco-lumbar sacral orthoses are
recommended for posture and to promote function. Cervical
bracing is often used for safety and transportation. Static,
dynamic and functional orthoses are used for positioning and
standing and, when possible, for supported ambulation.
Supported standing is important to facilitate lower extremity
stretching but also to promote bodily functions and bone health,
enable upright participation, and promote spine and trunk
posture.
2.4.2.3. Mobility and exercise. All sitters should have
electric/power wheelchairs with custom postural support and
seating systems. Assessments for power wheelchair mobility
can begin before 2 years of age [46]. Lightweight manual
wheelchairs or power assist wheels are ideal to promote self-
propulsion in stronger patients. Exercise programs and
activities that encourage muscle activation should be
encouraged since it can have an effect on maintaining and
improving function, strength, range of motion, endurance,
balance, activities of daily living, and participation in school,
social activities and occupation. Recommended exercise for
sitters include aquatic therapy, concentric and eccentric
exercise and aerobic and general conditioning exercise with
and without resistance.
2.4.2.4. Chest physiotherapy. Similar to non-sitters, chest
physiotherapy is an important part of the assessment and
management to implement, especially I the weak type 2, both as
prophylaxis and during illness or perioperative periods. Manual
techniques are similar to those reported for non-sitters.
2.4.3. Walkers
The main objectives for rehabilitation in walkers are to
maintain, restore or promote function, mobility, and adequate
joint range, and improve balance and endurance.
2.4.3.1. Exercise/activity programs. The exercise programs
will include many of the suggestions used for sitters. In
addition, some form of balance exercise, both, dynamic and
static forms, should also be part of an exercise program.
2.4.3.2. Stretching and range of motion. Modalities of
stretching and range of motion include: passive stretching and
active-assistive techniques. Lower limb orthoses are mainly
used for maintaining flexibility, posture and function at the
ankle and knee. Thoracic bracing is not typically used during
walking as it may adversely affect ambulation ability and limit
effective compensatory strategies but, when needed, may be
used to promote posture in sitting.
2.4.3.3. Mobility. To ensure functional independence,
lightweight manual wheelchairs or power assist wheels are
recommended when endurance is limited. Similarly, electric/
power wheelchairs or powered scooters may also be
considered to facilitate independent mobility over longer
distances.
2.5. Orthopedic management
2.5.1. Spine deformity management
2.5.1.1. Non-sitters. Until now, because of their limited
survival, spinal management was rarely discussed as a possible
option in non-sitters, unless they had stable respiratory and
nutritional function [3,47]. Specific rigid braces allowing stable
sitting position may be used, provided they do not compromise
pulmonary function (Fig. 3). Supine Cobb angle or that
obtained in the sitting position using a trunk brace may be used
in their follow up [47]. The advent of new therapies leading to
increased survival and overall functional improvements [7,8], is
rapidly changing the scenario of spinal management in these
patients.
2.5.1.2. Sitters.
2.5.1.2.1. Assessment. Scoliosis is still highly prevalent in
children with SMA 1 and 2, with incidence of 60–90% and
initial presentation in early childhood [1,48]. The hypotonic
spinal curves continuously progress through childhood.
Thoracic kyphosis also develops in most patients to a variable
degree.
Inspection of the spine should be conducted as part of the
routine clinical examination. When kyphoscoliosis is suspected
on forward bend test in sitting or standing posture, anterior-
posterior and lateral projection spine radiographs should be
performed in the most upright position independently
attainable by the patient (i.e. sitting in children who can sit
independently, standing in SMA 3) to define and quantify
the extent of spinal deformity in both coronal and sagittal
planes. For SMA 1 and 2 patients, scoliosis >20° should be
monitored every 6 months until skeletal maturity and yearly
after skeletal maturity. Management with spinal orthoses is
often advocated to support the hypotonic trunk and treat scoliosis
>20°, especially in a child with significant growth remaining
[42,49]. There was no consensus on the type of brace to be
used, as both rigid and soft spinal thoracolumbar orthoses were
recommended.
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2.5.1.2.2. Surgical intervention. Bracing is palliative and
unable to halt progression of spinal deformity [49,50]. As a
result, spinal instrumentation is frequently indicated to
preserve trunk balance in sitting, re-align the distorted thorax
to facilitate respiratory function and improve overall quality
of life [50–55]. The decision to surgically instrument the
spine is predicated mainly on curve magnitude (i.e. major
curve Cobb angle ≥50°) and rate of progression (≥10° per year).
Other factors, such as decreasing respiratory function,
parasol rib deformity, hyperkyphosis and adverse effects on
functional mobility, pelvic obliquity, and trunk imbalance
should also be considered. Pulmonary function tests
should be considered as part of the pre-operative evaluation
to determine surgical risk and post-operative respiratory
management.
There was consensus that surgical treatment of spine
deformity should be delayed until after the age of 4 years
(Supplementary Table S4).
In skeletally immature patients younger than 8 to 10 years,
“growth-friendly” instrumentation, that stabilizes and improves
spinal deformity, but allows for continued spine growth
should be considered [3,50,52,56–60]. To decrease the need
for repeated surgery, magnetically controlled growing rods
have recently been advocated [61] as an alternative to traditional
growing rods that require sequential surgical lengthenings
[62–65]. For children between the ages 8 to 12 years, there
was variability in practice among members of the expert
panel; the surgical approach depended on clinical variables,
especially skeletal maturity and spine growth remaining.
In nearly skeletally mature patients 12 years of age or
older, definitive posterior spine fusion using dual rod,
multi-segmental constructs should be implemented with or
without extension to the pelvis, depending on whether
the pelvis is part of the scoliotic curve [66]. While
there were no published studies on how to accommodate
for intrathecal access in patients undergoing spinal
instrumentation, there was consensus that one or two
mid-lumbar levels should be left unexposed in the midline to
accommodate intrathecal access, necessary for the administration
of recently approved drugs such as nusinersen, and antisense
oligonucleotide which does not cross the blood brain barrier.
Conversion of growth-friendly instrumentation to definitive
posterior spine fusion should be decided on a case-by-case
basis.
2.5.1.2.3. Chest deformity, thoracic insufficiency and
pulmonary health. As a consequence of poor trunk and
thoracic muscular support, children with SMA have an
increased incidence of thoracic insufficiency, the result of
scoliosis and distortion of the rib cage [50,67]. Collapse
of the ribs (similar to closing an umbrella) contributes to
“parasol rib” deformity [53,54,67–69]. Retrospective study of
children with hypotonic scoliosis treated with either rib- or
spine-based growth-friendly instrumentation systems have
shown poor efficacy in ameliorating parasol rib deformity
or increasing thoracic volume, and therefore are not
recommended [67].
2.5.1.2.4. Hip instability. Hip instability is common in
patients with SMA [3,50,55,70]. Several older studies
recommended against surgical repair, noting that surgically
treated hips tended to re-subluxate or dislocate, and that hip
pathology rarely caused pain [3,50,55,70]. However, these
studies failed to reflect modern surgical techniques and did not
evaluate young adult and middle-aged patients. Unilateral and
bilateral hip instability should be surgically managed only in
patients with significant pain.
2.5.1.2.5. Contractures. Contractures are common in
patients with SMA as a result of decreased range of motion,
prolonged static positioning, and agonist-antagonist muscle
imbalance [50,71,72]. Functionally and symptomatically,
contractures can lead to pain and inhibit function in patients
Fig. 3. Spine deformity management (VEPTR: Vertical Expandable Prosthetic Titanium Rib).
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with SMA [24,42–46,71–75]. Conservative management of
joint contractures has been discussed in the rehabilitation
section [24,42–46]. Surgical management of contractures of the
upper or lower extremities should be considered when they
cause pain or impair function.
2.5.1.2.6. Management of fractures. Owing to disuse,
osteoporosis and low vitamin D levels, fragility fractures are
common in children with SMA 1 and 2. Closed treatment with
cast immobilization is generally recommended for non-
ambulatory patients, but prolonged cast immobilization (>4
weeks) that aggravates muscle wasting and disuse osteoporosis
should be avoided. Ambulatory patients with long bone
fractures of the lower extremities and non-ambulatory
patients with hip fractures generally benefit from surgical
stabilization using intramedullary rods or bridging fracture
plates to restore immediate bone stability to allow early range
of motion of the extremity and to promote accelerated fracture
healing.
2.6. Nutritional management, swallowing and
gastrointestinal dysfunction
The main topics covered include swallowing dysfunction
and dysphagia, weight control and gastrointestinal dysfunction
(Table 2).
Table 2
Nutritional assessment and intervention.
Assessment Intervention Care considerations
Non-sitters Video Fluoroscopic Swallow Study
shortly after diagnosis and when
suggested by clinical signs
suggestive of dysphagia (weak suck,
fatigue, humid voice, pneumonias)
Difficulties with feeding (pocketing,
jaw contractures, increased
mealtimes)
Nutritional analysis of food
records/feeding regimen
Longitudinal anthropometrics
Acute care monitoring
25 Hydroxy-vitamin D labs and
Body Composition and Bone density
Constipation
If swallow study is passed, consider referral to specialist for
feeding therapy/modification
For failure of a swallow study or for growth failure, for
proactive care, place nasojejunal tube until a Gastric-tube can
be placed with Nissen fundoplication.
A dietitian should adjust caloric, fluid, macronutrient,
micronutrient intake and timing of feeds. Nutrition labs may
be indicated.
Minimize fasting during acute care to less than 6 hours.
Provide adequate fluid intake during illness. Monitor
electrolyte levels and correct as needed.
Monitor glucose levels to correct hypo/hyperglycemia.
Provide adequate calcium, vitamin D intakes for bonehealth.
Adequate hydration. Use of bowel regulation medications.
Determine appropriate calorie needs
based on growth. Standardized
growth charts are a good tool to
track growth trends, but optimally,
should be used with other body
composition measurement tools to
assess appropriate growth.
For optimal care, recommend
evaluation by a dietitian every 3–6
months for younger children and
annually for older children/adults.
Evaluation is especially important
for those on specialized diets.
Sitters Assessment of symptoms of
dysphagia/aspiration/Difficulties
with feeding
Video Fluoroscopic Swallow Study
if suggested by clinical signs
suggestive of dysphagia.
Nutritional analysis of food
records/feeding regimen
Longitudinal anthropometrics
(height, weight, OFC)
Nutrition labs may be indicated.
Acute care monitoring
Glucose metabolism labs
25 Hydroxy-vitamin D labs and
Body Composition and Bone density
(DXA)
Constipation
If safe to swallow, refer to specialist for feeding
therapy/modification.
If failed swallow or interventions are not sufficient place
nasofeeding tube as indicated prior to placement of a long
term Gastric feeding tube.
For growth failure, provide supplemental nutrition products.
Referral to dietitian for increasing calories with nutrient dense
foods.
Adjust caloric, fluid, macronutrient, and micronutrient intake
based on growth and intake.
Limit calorie intake in overweight individuals and maximize
nutrient intake.
Minimize fasting during acute care. Appropriate fasting time
depends on prior nutritional status and nature of acute event.
Provide adequate fluid intake during illness. Monitor
electrolyte levels and correct as needed.
Monitor glucose levels to correct hypo/hyperglycemia.
Indicated for individuals with increased body fat or other
prediabetic symptoms.
Adequate calcium, vitamin D intake.
Diets rich in fiber are recommended to promote gastric
motility and reduce constipation. Adequate fluid is needed
with increased fiber intakes. Bowel regulation medication may
be indicated.
At minimum, recommend evaluation
by a dietitian shortly after diagnosis
and for concerns of under/over
nutrition.
For optimal care, recommend
evaluation by a dietitian every 3–6
months for younger children and
annually for older children/adults.
Evaluation is especially important
for those on specialized diets.
Ambulant See dietitian for concerns of
over/under nutrition
Nutritional analysis/monitoring if
underweight or overweight
Longitudinal anthropometrics
(height, weight, OFC).
Glucose metabolism labs
25 Hydroxy-vitamin D labs
Provide macro/micronutrient intakes based on guidelines for a
healthy sedentary individual.
Limit calories as indicated to prevent obesity.
Minimize fasting during acute care
Indicated for individuals with increased body fat or other
prediabetic symptoms
Provide adequate calcium, vitamin D intakes for bonehealth if
needed
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For all SMA types regular assessments of growth are
important and an expert nutritionist should be involved to
promote an appropriate diet, monitoring not only weight but
also fluid, macronutrient, and micronutrient intake, especially
calcium and vitamin D intake for bone health [76–78]. SMA-
specific growth charts are not yet available. Secondary to
altered body composition in SMA [79–81], experts are divided
in the use of standardized growth charts alone to monitor
appropriate growth, but they may be helpful to monitor trends.
In all types it is important to ask and document details
regarding GI symptoms such as presence of gastroesophageal
reflux, constipation, use of bowel regulatory agents, delayed
gastric emptying, and vomiting.
Over the last few years there has also been increasing
evidence of possible metabolic abnormalities in SMA patients
such as metabolic acidosis, abnormal fatty acid metabolism,
hyperlipidemia, hyperglycemia, hypoglycemia, and muscle
mitochondria defects [82–84]. Perturbations of glucose
metabolism and pancreatic development have been reported in
SMA mice [85–89]. Glucose metabolism abnormalities were
later confirmed in some obese SMA patients [90,91] and
pancreatic differences confirmed in deceased SMA 185.
2.6.1. Non sitters
2.6.1.1. Assessment. Safe swallowing is one of the most
important aspects to consider for a non-sitter (Supplementary
Table S5). Bulbar dysfunction can result in aspiration and
pulmonary infections. A full modified barium swallow
fluoroscopic study is recommended shortly after diagnosis and,
if the initial test is normal, closely monitored to detect possible
early signs of feeding difficulties. Contracture of the masseter
muscles often develops in patients by one year of age and limits
the opportunity for oral feeding. This may be a limiting factor
for patients treated with nusinersen who demonstrate
improvement in bulbar muscle strength.
Optimal nutritional management includes longitudinal
evaluation of weight and length and dietary analysis. In type 1
patients, masticatory muscle weakness, dysphagia and
respiratory problems are responsible for reduced calorie intake
and risk of undernutrition. Additionally, increased work of
breathing may increase energy expenditure and caloric
requirements, further increasing the risk of undernutrition.
2.6.1.2. Intervention. For proactive care following a failed
swallow study or growth failure, placement of a short-term
nasogastric or nasojejunal tube is recommended until long term
gastrostomy tube can be placed. There was no unanimous
consensus but many experts prefer that Nissen fundoplication
be performed in conjunction with gastrostomy tube placement
secondary to decreased gastrointestinal motility, reflux, and
increased pressure related to respiratory treatments [92]
(Supplementary Table S6).
There is less consensus on the effect of the type of diet [12].
Consensus is divided on the use of the Amino Acid diet, a diet
based on elemental formula [83,93]. Experts agreed that diet
type and administration should be based on individual
tolerance. Adequate hydration as well as bowel regulating
agents, probiotics, and motility medications are recommended
to ease symptoms of constipation and gastrointestinal
dysmotility.
Regarding nutritional aspects during acute care in non-
sitters, it has been strongly suggested that fasting should
be avoided to prevent including metabolic acidosis, fatty
acid metabolism abnormalities, and hyper/hypoglycemia
[82,83,93–95]. Divided expert opinion suggests that nutrition
including a protein source should be provided within 6 hours
during acute episodes. Adequate hydration and electrolyte
balance is imperative during illness.
2.6.2. Sitters
2.6.2.1. Assessment. For optimal care, nutrition evaluations
are recommended after diagnosis and periodically, every 3–6
months for younger children and annual evaluations afterwards.
Chewing difficulties and fatigue with eating, are frequent in
sitters [96,97]. Safe swallowing and risk of aspiration are also a
concern. A history of choking or coughing episodes with feeds
should be investigated and monitored with swallow studies.
Feeding evaluations are also recommended for possible
feeding modifications/occupational therapy in order to swallow
safely and eat effectively.
Longitudinal measures of weight and length in conjunction
with body composition measures are recommended to promote
appropriate growth.
Evaluation for obesity as well as glucose metabolism
abnormalities may be recommended for overweight sitters.
Some experts suggest that sitters with SMA should be evaluated
for possibility of obesity/overfat at BMI greater than the 25th
percentile [91].
Evaluation of fluid and fiber intake is recommended for
frequent constipation.
2.6.2.2. Intervention. In a case series study 37% of sitters have
growth failure and require intervention [96]. Feeding tubes are
commonly used in this population for supplementary nutrition
rather than total nutrition and suggestions for feeding tubes and
GI surgical recommendations depend on the individual
situation.
Sitters may be at risk for being overweight/obese as they
grow older secondary to the reduction in physical activity due
to weakness and altered body composition [80,91]. Concerns
for overweight include reduced mobility and risks for related
comorbidities including risk of metabolic syndrome [86,93].
Diet is variable in sitters. Calories, protein, fat and
carbohydrate, are initially estimated using common standardized
equations [98] and should be adjusted as appropriate growth
and labs indicate. There is lack of consensus on the use of the
amino acid diet and no data to support the use of synthetic
amino acid as opposed to intact protein in patients with
SMA.
Based on experience and case studies [93–95] experts
recommend that fasting times should be limited during acute
circumstances and electrolyte and fluids should be monitored
and repleted as indicated.
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Depending on severity of constipation, fiber intake,
probiotics, and bowel regulating agents may be used to improve
symptoms.
2.6.3. Walkers
In this population, swallowing dysfunction and feeding
difficulties are rare. A dietitian/nutrition evaluation is
recommended if there are nutritional issues. The largest
nutritional concerns for walkers with SMA is the risk of obesity
and overweight as this can reduce mobility and may increase
risk of obesity-related comorbidities such as metabolic
syndrome, high blood pressure, and diabetes.
2.6.3.1. Bone health. It has been recognized that SMN has a
specific role in the metabolism of the bone interacting with
osteoclast stimulatory factor osteoclast stimulatory factor [99].
Therefore, the high incidence of osteopenia and fractures in
SMA patients may not be simply attributed to muscle weakness
and lack of exercise [76,100,101]. Periodic Dual energy x-ray
absorptiometry analysis (DEXA) to monitor bone density in
patients with SMA, is recommended yearly. There was
consensus among experts that Vitamin D blood levels and
intake should be monitored at least annually and supplements
should be given in the presence of low levels or of osteopenia.
In the case of frequent fracture, review may be given to use of
bisphosphonates.
3. Conclusions
The recommendations reported in this first part provide an
overview of what should be considered standard of care for
SMA. The paper highlights the importance of a
multidisciplinary approach and of the role of the neurologist/
pediatric neurologist in coordinating, together with the families,
the various aspects of care.
In all the aspects of care included, there was often not
enough published evidence and the recommendations were the
results of what was available from the literature and experts’
opinion, following a well-established Delphi method to classify
consensus and appropriateness of assessments and
interventions. The working groups identified the aspects that
constitute optimal care but considering that some of the
recommendations may not be easily applicable in centers or
countries with less resources, an effort was made to identify
assessments or interventions that constitute the minimal care
that families should expect to find in any neuromuscular
centre.
The second part of the two-part paper will focus on other
aspects of care, such as pulmonary and acute care, involvement
of other organs, medications and ethical issues.
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